...
首页> 外文期刊>International Journal of Hematology >Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome
【24h】

Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome

机译:骨髓源性CD34 +细胞的差异基因表达与骨髓增生异常综合征患者的生存相关

获取原文
获取原文并翻译 | 示例

摘要

One feature of the molecular pathology of myelodysplastic syndromes (MDS) is aberrant gene expression. Such aberrations may be related to patient survival, and may indicate to novel diagnostic and therapeutic targets. Therefore, we aimed at identifying aberrant gene expression that is associated with MDS and patient survival. Bone marrow-derived CD34+ hematopoietic progenitor cells from six healthy persons and 16 patients with MDS were analyzed on cDNA macroarrays comprising 1,185 genes. Thereafter, our patients were followed-up for 54 months. We found differential expression of genes that were hitherto unrecognized in the context of MDS. Differential expression of 10 genes was confirmed by quantitative real-time RT-PCR. Hierarchical cluster analysis facilitated the separation of CD34+ cells of normal donors from patients with MDS. More importantly, it also distinguished MDS-patients with short and long survival. Scrutinizing our cDNA macroarray data for genes that are associated with short survival, we found, among others, increased expression of six different genes that encode the proteasome subunits. On the other hand, the most differentially down-regulated gene was IEX-1, which encodes an anti-apoptotic protein. We confirmed its decreased expression on RNA and protein level in an independent validation set of patient samples. The presented data broadens our notion about the molecular pathology of MDS and may lend itself to better identify patients with short survival. Furthermore, our findings may help to define new molecular targets for drug development and therapeutic approaches for patients with poor prognosis.
机译:骨髓增生异常综合症(MDS)的分子病理学特征之一是异常的基因表达。这样的像差可能与患者的存活有关,并且可能指示新的诊断和治疗靶标。因此,我们旨在鉴定与MDS和患者生存相关的异常基因表达。在包含1,185个基因的cDNA宏阵列上分析了来自6名健康人和16名MDS患者的骨髓来源的CD34 +造血祖细胞。此后,对我们的患者进行了54个月的随访。我们发现迄今为止在MDS上下文中未被认识的基因的差异表达。通过定量实时RT-PCR证实了10个基因的差异表达。层次聚类分析有助于从MDS患者中分离正常供体的CD34 +细胞。更重要的是,它还区分了具有短期生存期和长期生存期的MDS患者。通过仔细研究与短生存期相关的基因的cDNA宏阵列数据,我们发现,除其他外,编码蛋白酶体亚基的六个不同基因的表达增加。另一方面,差异最大的下调基因是IEX-1,它编码一种抗凋亡蛋白。我们在一组独立的患者样本验证中证实了其在RNA和蛋白质水平上的表达降低。提出的数据拓宽了我们对MDS分子病理学的认识,并可能有助于更好地识别生存期短的患者。此外,我们的发现可能有助于为预后不良的患者确定药物开发和治疗方法的新分子靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号